Core Insights - Turn Therapeutics Inc. has appointed Mr. Martin Dewhurst to its Board of Directors, bringing over 30 years of experience in life sciences and M&A, aligning with the company's strategic goals for growth and expansion [1][2] Company Overview - Turn Therapeutics is a clinical-stage biotechnology company focused on developing targeted therapies for dermatology, advanced wound care, and infectious diseases [1][5] - The company has received three FDA clearances for its proprietary formulations and is advancing late-stage clinical programs in eczema and onychomycosis [5] Strategic Focus - The appointment of Mr. Dewhurst is seen as pivotal for Turn Therapeutics as it pursues a disciplined, M&A-focused strategy to expand its pipeline and create long-term value [2] - Mr. Dewhurst's expertise in capital allocation, portfolio expansion, and partnership development will be instrumental in evaluating opportunities that complement Turn's platform [2][3] Leadership Background - Mr. Dewhurst has a significant background in the life sciences industry, having co-led McKinsey & Company's global life sciences practice and co-founded the McKinsey Health Institute [2][3] - He also serves as a senior advisor to PJT Partners and holds board positions in various organizations, including a Switzerland-based medtech company [3] Commitment to Public Health - Turn Therapeutics is pursuing global health initiatives, including thermostable vaccine delivery aimed at underserved areas, reflecting its commitment to public health innovation [5]
Turn Therapeutics Appoints Martin Dewhurst to its Board of Directors